{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T16:44:45Z","timestamp":1769359485748,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12325-017-0618-4","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T07:06:00Z","timestamp":1507619160000},"page":"2345-2359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacotherapy Choice Is Associated with 2-Year Mortality for Patients with Heart Failure and Reduced Ejection Fraction"],"prefix":"10.1007","volume":"34","author":[{"given":"Nancy M.","family":"Albert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana A.","family":"Drzayich Antol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"DeClue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianne Waldman","family":"Casebeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Stemkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Lan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"618_CR1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics\u20142017 update: a report from the american heart association. Circulation. 2017;135:e146\u2013603.","journal-title":"Circulation."},{"issue":"4","key":"618_CR2","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29\u2013322.","journal-title":"Circulation"},{"issue":"3","key":"618_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","volume":"171","author":"C Cook","year":"2014","unstructured":"Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368\u201376. doi:\n                        10.1016\/j.ijcard.2013.12.028\n                        \n                     Epub Dec 22.","journal-title":"Int J Cardiol"},{"issue":"3","key":"618_CR4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation Heart failure. 2013;6(3):606\u201319.","journal-title":"Circulation Heart failure."},{"issue":"16","key":"618_CR5","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013239. doi:\n                        10.1016\/j.jacc.2013.05.019\n                        \n                     Epub Jun 5.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"618_CR6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"The Digitalis Investigation Group","year":"1997","unstructured":"The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525\u201333.","journal-title":"N Engl J Med"},{"issue":"16","key":"618_CR7","first-page":"33024","volume":"17","author":"CW Yancy","year":"2016","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;17(16):33024\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"9744","key":"618_CR8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875\u201385.","journal-title":"Lancet"},{"issue":"11","key":"618_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. doi:\n                        10.1056\/NEJMoa1409077\n                        \n                     (Epub 2014 Aug 30).","journal-title":"N Engl J Med"},{"issue":"23","key":"618_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","unstructured":"The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"618_CR11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","journal-title":"N Engl J Med"},{"issue":"9386","key":"618_CR12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772\u20136.","journal-title":"Lancet"},{"issue":"13","key":"618_CR13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","volume":"66","author":"JJ Goldberger","year":"2015","unstructured":"Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66(13):1431\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"618_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"B Pitt","year":"2005","unstructured":"Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30\u00a0days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"5 Pt 2","key":"618_CR15","first-page":"Iv49","volume":"75","author":"JN Cohn","year":"1987","unstructured":"Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation. 1987;75(5 Pt 2):Iv49\u201354.","journal-title":"Circulation."},{"issue":"1","key":"618_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2008.06.068","volume":"103","author":"A Ahmed","year":"2009","unstructured":"Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, et al. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol. 2009;103(1):82\u20137.","journal-title":"Am J Cardiol"},{"issue":"3","key":"618_CR17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijcard.2003.10.018","volume":"97","author":"AV Mattioli","year":"2004","unstructured":"Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol. 2004;97(3):383\u20138.","journal-title":"Int J Cardiol"},{"issue":"5","key":"618_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303\u201310.","journal-title":"N Engl J Med"},{"issue":"10","key":"618_CR19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"618_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/clpt.2013.146","volume":"94","author":"O Vardeny","year":"2013","unstructured":"Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther. 2013;94(4):445\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"618_CR21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrcardio.2010.179","volume":"7","author":"CM Terracciano","year":"2010","unstructured":"Terracciano CM, Yacoub MH. Heart failure: a SHIFT from ion channels to clinical practice. Nat Rev Cardiol. 2010;7(12):669\u201370.","journal-title":"Nat Rev Cardiol."},{"issue":"1","key":"618_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/pds.4132","volume":"26","author":"S Perreault","year":"2017","unstructured":"Perreault S, de Denus S, White M, White-Guay B, Bouvier M, Dorais M, et al. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Pharmacoepidemiol Drug Saf. 2017;26(1):81\u201390.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"618_CR23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3889\/oamjms.2016.022","volume":"4","author":"B Taneva","year":"2016","unstructured":"Taneva B, Caparoska D. The impact of treatment with beta-blockers upon mortality in chronic heart failure patients. Open Access Maced J Med Sci. 2016;4(1):94\u20137.","journal-title":"Open Access Maced J Med Sci."},{"issue":"2","key":"618_CR24","doi-asserted-by":"crossref","first-page":"e002597","DOI":"10.1161\/CIRCHEARTFAILURE.115.002597","volume":"9","author":"PB Nielsen","year":"2016","unstructured":"Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skj\u00f8th F, Lip GYH. \u03b2-Blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study. Circ Heart Fail. 2016;9(2):e002597.","journal-title":"Circ Heart Fail."},{"key":"618_CR25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12872-016-0198-2","volume":"16","author":"M-D Chen","year":"2016","unstructured":"Chen M-D, Dong S-S, Cai N-Y, Fan M-D, Gu S-P, Zheng J-J, et al. Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:28.","journal-title":"BMC Cardiovasc Disord."},{"issue":"1","key":"618_CR26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12872-016-0418-9","volume":"16","author":"TB Abebe","year":"2016","unstructured":"Abebe TB, Gebreyohannes EA, Tefera YG, Abegaz TM. Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. BMC Cardiovasc Disord. 2016;16(1):232.","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"618_CR27","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.amjcard.2013.08.014","volume":"112","author":"A Mangla","year":"2013","unstructured":"Mangla A, Kane J, Beaty E, Richardson D, Powell LH, Calvin JE Jr. Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol. 2013;112(12):1907\u201312.","journal-title":"Am J Cardiol"},{"issue":"8","key":"618_CR28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cardfail.2011.04.011","volume":"17","author":"AA Fitzgerald","year":"2011","unstructured":"Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Cardiac Fail. 2011;17(8):664\u20139.","journal-title":"J Cardiac Fail"},{"issue":"7","key":"618_CR29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00059-016-4401-0","volume":"41","author":"S Neubauer","year":"2016","unstructured":"Neubauer S, Schilling T, Zeidler J, Lange A, Engel S, Linder R, et al. Impact of guideline adherence on mortality in treatment of left heart failure. Herz. 2016;41(7):614\u201324.","journal-title":"Herz."},{"key":"618_CR30","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7022.1","author":"T Kitai","year":"2015","unstructured":"Kitai T, Tang WW. Recent advances in treatment of heart failure. 1000Res. 2015. doi:\n                        10.12688\/f1000research.7022.1\n                        \n                     (eCollection 2015).","journal-title":"1000Res"},{"issue":"14","key":"618_CR31","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","volume":"119","author":"M Jessup","year":"2009","unstructured":"Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: aCCF\/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009;119(14):1977\u20132016.","journal-title":"Circulation"},{"issue":"6","key":"618_CR32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"618_CR33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ki.2011.388","volume":"81","author":"J Liu","year":"2012","unstructured":"Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding \u2018immortal time\u2019 in the analysis of the treatment effects in observational studies. Kidney Int. 2012;81(4):341\u201350.","journal-title":"Kidney Int"},{"issue":"5","key":"618_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.18553\/jmcp.2016.22.5.561","volume":"22","author":"C Deschaseaux","year":"2016","unstructured":"Deschaseaux C, McSharry M, Hudson E, Agrawal R, Turner SJ. Treatment initiation patterns, modifications, and medication adherence among newly diagnosed heart failure patients: a retrospective claims database analysis. J Manag Care Spec Pharm. 2016;22(5):561\u201371. doi:\n                        10.18553\/jmcp.2016.22.5.561\n                        \n                    .","journal-title":"J Manag Care Spec Pharm."},{"issue":"2","key":"618_CR35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/phar.1701","volume":"36","author":"AP Bress","year":"2016","unstructured":"Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, et al. pharmacotherapy treatment patterns, outcomes, and health resource utilization among patients with heart failure with reduced ejection fraction at a U.S. Academic Medical Center. Pharmacotherapy. 2016;36(2):174\u201386.","journal-title":"Pharmacotherapy."},{"issue":"5","key":"618_CR36","doi-asserted-by":"publisher","first-page":"750.e1","DOI":"10.1016\/j.ahj.2012.08.002","volume":"164","author":"BD Atwater","year":"2012","unstructured":"Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, et al. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. Am Heart J. 2012;164(5):750.e1\u2013755.e1. doi:\n                        10.1016\/j.ahj.2012.08.002\n                        \n                     (Epub Oct 16).","journal-title":"Am Heart J."},{"issue":"9961","key":"618_CR37","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","volume":"384","author":"D Kotecha","year":"2014","unstructured":"Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF, et al. Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235\u201343.","journal-title":"Lancet."},{"issue":"20","key":"618_CR38","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, Carson P, D\u2019Agostino RJ, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"618_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0618-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T09:34:00Z","timestamp":1508924040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0618-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0618-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}